PHVS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

34.740

Open

33.550

VWAP

34.16

Vol

972.78K

Mkt Cap

2.40B

Low

33.160

Amount

33.23M

EV/EBITDA(TTM)

Total Shares

69.28M

2.03B

EV/OCF(TTM)

P/S(TTM)

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Events Timeline

(ET)

2026-05-12

16:30:00

Pharvaris Cash and Cash Equivalents Drop to €247 Million

2026-04-20 (ET)

2026-04-20

07:00:00

Pharvaris Presents Deucrictibant Data at CIIC Conference

News

9.0

07-06NASDAQ.COM

PinnedPharvaris' New Drug Application Accepted by FDA for Deucrictibant

8.5

07-06Newsfilter

PinnedPharvaris Receives FDA Acceptance for New Drug Application

9.0

07-06NASDAQ.COM

Pharvaris' NDA for Deucrictibant Accepted by FDA

8.5

05-29Newsfilter

Pharvaris to Present Research Findings at EAACI Congress

9.5

05-12seekingalpha

Pharvaris Reports Q1 2026 Financial Results

5.0

05-11Fool

Analysis of Insider Stock Transaction at Pharvaris N.V.

9 Analyst Rating

Wall Street analysts forecast PHVS stock price to rise

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

41.00

High

60.00

Current: 0.000

Low

30.00

Averages

41.00

High

60.00

Morgan Stanley

Maxwell Skor

Overweight

maintain

$41 -> $46

AI Analysis

2026-06-25

Reason

Morgan Stanley

Maxwell Skor

Price Target

$41 -> $46

AI Analysis

2026-06-25

maintain

Overweight

Reason

Morgan Stanley analyst Maxwell Skor raised the firm's price target on Pharvaris to $46 from $41 and keeps an Overweight rating on the shares. Noting that topline data is on track for Q3 for the pivotal Phase 3 CHAPTER-3 trial for prophylactic treatment, the firm continues to see a differentiated profile for deucrictibant across both the on-demand and prophylactic settings.

BofA

David Nassif

Neutral

maintain

$31 -> $33

2026-05-14

Reason

BofA

David Nassif

Price Target

$31 -> $33

2026-05-14

maintain

Neutral

Reason

BofA raised the firm's price target on Pharvaris to $33 from $31 and keeps a Neutral rating on the shares after having hosted CFO David Nassif for a fireside chat at the firm's Healthcare Conference. The firm rolls its valuation for the quarter and updates estimates for Q1 results, cash and share count, citing lower operating expense estimates and higher net cash contribution for its revised target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHVS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Pharvaris NV (PHVS.O) is 0.00, compared to its 5-year average forward P/E of -6.55. For a more detailed relative valuation and DCF analysis to assess Pharvaris NV's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.55

Current PE

0.00

Overvalued PE

-4.31

Undervalued PE

-8.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.75

Undervalued EV/EBITDA

-6.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.77

Current PS

58.73

Overvalued PS

14.34

Undervalued PS

-8.81

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best stock for swing traders tomorrow

Intellectia · 75 candidates

Price: $5.00 - $100.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20One Day Rise Prob: >= 60Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

DNLI

Denali Therapeutics Inc

3.15B

MITK

Mitek Systems Inc

647.57M

SXC

SunCoke Energy Inc

552.33M

RDWR

Radware Ltd

1.10B

DHT

DHT Holdings Inc

2.91B

PHVS

Pharvaris NV

1.87B

단기 데이트레이닝에서 변동성이 5%로 예상되는 오늘 주식을 추천해줘

Intellectia · 11 candidates

Price: >= $5.00Price Change Pct: $3.00 - $7.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

ARVN

Arvinas Inc

724.68M

UNIT

Uniti Group Inc (Delaware)

2.39B

CALM

Cal-Maine Foods Inc

3.95B

ANGO

AngioDynamics Inc

492.14M

SMFG

Sumitomo Mitsui Financial Group, Inc

132.71B

HOPE

Hope Bancorp Inc

1.50B

which stocks will decrease this week

Intellectia · 42 candidates

Region: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossDownMA5, PriceBelowMA20Week Price Change Pct: $-100.00 - $-2.00One Week Rise Prob: 0 - 40One Week Predict Return: -100.0% - -2.0%

Ticker

Name

Market Cap$

SYK

Stryker Corp

125.81B

VTR

Ventas Inc

39.03B

VEEV

Veeva Systems Inc

29.25B

RYTM

Rhythm Pharmaceuticals Inc

5.64B

DBX

Dropbox Inc

5.58B

CRSP

CRISPR Therapeutics AG

4.46B

which stocks show a great upside

Intellectia · 35 candidates

Analyst Consensus: Strong BuyBeta: LowRiskWeekly Average Turnover: >= 1,000,000Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

LNG

Cheniere Energy Inc

44.62B

VNOM

Viper Energy Inc

14.18B

TTEK

Tetra Tech Inc

9.59B

PRAX

Praxis Precision Medicines Inc

8.57B

CORZ

Core Scientific Inc

5.64B

ALKS

Alkermes Plc

5.59B

Whales Holding PHVS

Logos Global Management, L.P.

Deerfield Management Company, L.P.

Sofinnova Investments, Inc.

General Atlantic Service Company, L.P.

Kynam Capital Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Pharvaris NV (PHVS) stock price today?

The current price of PHVS is 34.59 USD — it has increased 4.12

What is Pharvaris NV (PHVS)'s business?

What is the price predicton of PHVS Stock?

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is41.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.